<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17077" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acetazolamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdullah</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Layton Rahmatullah Eye Hospital Lahore</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Abdullah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17077.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Acetazolamide is a diuretic and carbonic anhydrase inhibitor medication used to treat several illnesses. It works to cause an accumulation of carbonic acid by preventing its breakdown. FDA-approved indications include glaucoma, idiopathic intracranial hypertension, congestive heart failure, altitude sickness, periodic paralysis, and epilepsy. In addition, it is used off-label for central sleep apnea, Marfan syndrome, prevention of high-dose methotrexate nephrotoxicity, and prevention of contrast-induced nephropathy. This activity outlines the indications, contraindications, interactions, monitoring, and other therapeutic information pertinent to members of an interprofessional team in the care of patients with conditions requiring the use of acetazolamide.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for acetazolamide, both FDA-approved and off-label.</p></list-item><list-item><p>Describe the mechanism of action of acetazolamide.</p></list-item><list-item><p>Summarize the adverse event profile of acetazolamide.</p></list-item><list-item><p>Explain the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care with acetazolamide therapy to improve patient outcomes for patients with indicated conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17077&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17077">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17077.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Acetazolamide is a diuretic and carbonic anhydrase inhibitor medication used to treat several illnesses, as&#x000a0;summarized&#x000a0;below.<xref ref-type="bibr" rid="article-17077.r1">[1]</xref></p>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Glaucoma<xref ref-type="bibr" rid="article-17077.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Idiopathic intracranial hypertension<xref ref-type="bibr" rid="article-17077.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Congestive heart failure<xref ref-type="bibr" rid="article-17077.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Altitude sickness<xref ref-type="bibr" rid="article-17077.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Periodic paralysis<xref ref-type="bibr" rid="article-17077.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Epilepsy<xref ref-type="bibr" rid="article-17077.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Central sleep apnea<xref ref-type="bibr" rid="article-17077.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Marfan syndrome<xref ref-type="bibr" rid="article-17077.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Prevention of high-dose methotrexate&#x000a0;nephrotoxicity<xref ref-type="bibr" rid="article-17077.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Prevention of contrast-induced nephropathy<xref ref-type="bibr" rid="article-17077.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>Acetazolamide is a classic treatment option for glaucoma as it causes a reduction in aqueous humor. It is also useful for treating altitude sickness because of its underlying mechanism of action. The medication works to excrete bicarbonate. Doing so alkalizes the urine as there is greater bicarbonate in the urine. As a result, the blood is more acidic, given that the bicarbonate has been excreted. Some mechanisms equate the carbon dioxide concentrations in the body to the degree of acidity, resulting in an artificial compensatory mechanism for what the body believes to be excess carbon dioxide. This compensation results in faster and deeper breathing. The outcome of that is higher oxygen concentrations in the body, which improves the ability of the body to adjust itself to the higher altitude levels.<xref ref-type="bibr" rid="article-17077.r12">[12]</xref></p>
      </sec>
      <sec id="article-17077.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Acetazolamide is a carbonic anhydrase inhibitor. That means this drug works to cause an accumulation of carbonic acid by preventing its breakdown. The result is lower blood pH (i.e., more acidic), given the increased carbonic acid, which has a reversible reaction into bicarbonate and a hydrogen ion.</p>
        <p>Carbonic&#x000a0;anhydrase is found in the proximal tubule of the&#x000a0;nephron and red blood cells. It works to reabsorb sodium, bicarbonate, and chloride. Once acetazolamide inhibits carbonic anhydrase, sodium, bicarbonate, and chloride get excreted rather than reabsorbed; this also leads to the excretion of excess water. The clinical result is a decrease in blood pressure, decreased intracranial pressure, and decreased intraocular pressure. Bicarbonate excretion also increases the acidity of the blood. Aqueous humor levels decrease in the eyes, and there are compensatory mechanisms for increased blood acidity, for example, hyperventilation.</p>
        <p>The entire process of excretion inhibited by carbonic anhydrase is essentially&#x000a0;working to acidify the urine and reabsorb bicarbonate. Acetazolamide will derange the whole process by increasing sodium in the urine and increasing bicarbonate which alkalinizes the urine. Diuresis is the other result.<xref ref-type="bibr" rid="article-17077.r12">[12]</xref></p>
        <p>In the eye, the inhibitory activity of acetazolamide reduces the secretion of aqueous humor resulting in a reduction in intraocular pressure, which is beneficial for glaucoma.&#x000a0;Acetazolamide is also used in treating idiopathic intracranial hypertension, as it inhibits enzymes in the choroid plexus and reduces the production of CSF, resulting in a decrease in intracranial pressure(ICP).<xref ref-type="bibr" rid="article-17077.r13">[13]</xref></p>
        <p>In epilepsy, inhibition of carbonic anhydrase by acetazolamide seems to retard abnormal, excessive, paroxysmal electrical discharge from neurons.&#x000a0;Carbonic anhydrase expression is extensively detected in CNS. Carbonic anhydrase inhibitor acetazolamide affects the delicate equilibrium among CO2, H+, and HCO3- in the&#x000a0;neurons and modulates the activity of ligand-gated ion channels at the neuronal level, such as GABA-A signaling. In addition, studies report their capacity to modulate Ca2+ kinetics through ligand-gated Ca2+ channels and voltage-gated Ca2+ channels (VGCC).&#x000a0;Carbonic anhydrases rapidly decrease or increase H+ and HCO3 &#x02212; in the neurons. Acetazolamide modulates the abnormal GABA-A-mediated depolarization that generates epileptic waves and has been shown to block epileptiform activity by inhibiting HCO3 -efflux. The integration of the above-illustrated&#x000a0;mechanisms may&#x000a0;explain&#x000a0;the antiepileptic effect of acetazolamide.<xref ref-type="bibr" rid="article-17077.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold> Well absorbed</p>
        <p>Distribution: Carbonic anhydrase inhibitors such as acetazolamide are avidly bound by carbonic anhydrase; consequently, tissues rich in enzymes, such as kidneys and RBC, will have higher concentrations of carbonic anhydrase inhibitors (acetazolamide)</p>
        <p><bold>Metabolism:</bold> Acetazolamide does not undergo metabolic alteration.</p>
        <p><bold>Excretion:</bold> Plasma half-Life: 6-9 hours; renal excretion is the primary route of elimination.</p>
      </sec>
      <sec id="article-17077.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Patients take acetazolamide with or without food and should drink plenty of fluids with the medication. Available dosages are 125 mg, 250 mg, and 500 mg tablets.<xref ref-type="bibr" rid="article-17077.r15">[15]</xref> These are also available in instant-release&#x000a0;and extended-release drug dosage forms.</p>
        <p>Intravenous (IV) administration of acetazolamide is available. However, intramuscular (IM) administration of acetazolamide&#x000a0;is not recommended.</p>
        <p>The dose range recommended for the treatment of glaucoma is 250 mg per day to 1000 mg per day. Typically, the dose will be 250 to 500 mg per day. For treating altitude sickness, the range is 250 to 500 mg daily in 2 oral doses.<xref ref-type="bibr" rid="article-17077.r15">[15]</xref> Lower doses are recommended when treating edema, epilepsy, and diuresis in congestive heart failure. The range used for those conditions is usually 250 to 375 mg. However, epilepsy may require higher dosages, up to 1000 mg daily.</p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p><bold>Patients with Renal Impairment: </bold>Use is not recommended in&#x000a0;cases of marked kidney disease.</p>
        <p><bold>Patients with Hepatic Impairment: </bold>Acetazolamide is&#x000a0;contraindicated in cirrhosis because of the risk of developing hepatic encephalopathy.</p>
        <p><bold>Pregnancy Considerations:</bold>&#x000a0;The use&#x000a0;of acetazolamide in&#x000a0;pregnancy&#x000a0;has not been recommended because of teratogenic effects in&#x000a0;preclinical studies.&#x000a0;But&#x000a0;in a study of pregnant patients with idiopathic intracranial hypertension,&#x000a0;no conclusive evidence of the adverse effects of acetazolamide during pregnancy was observed.<xref ref-type="bibr" rid="article-17077.r16">[16]</xref>&#x000a0;Acetazolamide was a Category C drug under the prior FDA pregnancy categorization system and should only be used in pregnancy if the benefits outweigh the risks to the unborn baby. Consequently, clinicians should&#x000a0;prescribe&#x000a0;acetazolamide only when indicated.</p>
        <p><bold>Breastfeeding Considerations: </bold>Data suggests that maternal doses of acetazolamide up to 1000 mg daily deliver low levels in milk and would not be anticipated to cause any adverse effects in breastfed infants. In addition, various international professional&#x000a0;guidelines consensus that carbonic anhydrase inhibitors such as acetazolamide are acceptable in breastfeeding.<xref ref-type="bibr" rid="article-17077.r17">[17]</xref></p>
      </sec>
      <sec id="article-17077.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>There is a broad range of general and specific adverse effects that acetazolamide use can induce. Fatigue, nausea, vomiting, abdominal pain, and diarrhea&#x000a0;are common in patients. Other patients will experience paresthesia, black stools, decreased libido, tinnitus, and taste alteration. There are also reports of patients developing depression while using acetazolamide or developing a bitter or metallic taste. Less commonly, there is a risk of developing metabolic acidosis, hyponatremia, and hypokalemia. Kidney stones can also be seen but are uncommon. Occasionally, patients develop Stevens-Johnson syndrome, aplastic anemia, agranulocytosis, toxic epidermal necrolysis, or fulminant hepatic necrosis.<xref ref-type="bibr" rid="article-17077.r18">[18]</xref></p>
        <p>Common side effects of this medication include fatigue, abdominal pain, nausea, vomiting, and paresthesia. Rare side effects, such as Stevens-Johnson syndrome, also exist. The drug can be administered orally as well as via the intravascular route. It should not be used by those with impaired renal or hepatic function. The medication is also known to interact with certain antibiotics, sodium bicarbonate, amphetamines, and salicylates.<xref ref-type="bibr" rid="article-17077.r19">[19]</xref></p>
      </sec>
      <sec id="article-17077.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Since acetazolamide decreases the clearance of ammonia, patients with impaired liver function or liver disease should not use acetazolamide.<xref ref-type="bibr" rid="article-17077.r20">[20]</xref> Usage may precipitate the development of hepatic encephalopathy.</p>
        <p>Acetazolamide can induce electrolyte abnormalities. As such,&#x000a0;those with&#x000a0;hypokalemia or hyponatremia should not use it. Similarly,&#x000a0;it can decrease kidney function, and clinicians should avoid using it with anyone with kidney disease or decreased kidney function.</p>
        <p>Patients with hyperchloremic acidosis should not use acetazolamide.<xref ref-type="bibr" rid="article-17077.r21">[21]</xref></p>
        <p>Although acetazolamide does not cause prolongation of the QTc interval, those with prolonged QTc should use it cautiously and have their potassium concentrations monitored, given the drug's ability to cause hypokalemia.</p>
        <p>Patients with an allergy to sulfonamides (e.g., sulfa allergy) should not use acetazolamide.<xref ref-type="bibr" rid="article-17077.r22">[22]</xref><xref ref-type="bibr" rid="article-17077.r21">[21]</xref></p>
        <p>Acetazolamide&#x000a0;is known&#x000a0;to interact with several classes of medications. A patient on amphetamines will likely develop reduced amphetamine clearance because acetazolamide increases the urine pH. In contrast, it increases the excretion of lithium, and hence its efficacy may be reduced. Acetazolamide also decreases the excretion of phenytoin, primidone, and quinidine. Patients on these medications may develop toxicity if they also use acetazolamide concurrently.<xref ref-type="bibr" rid="article-17077.r23">[23]</xref><xref ref-type="bibr" rid="article-17077.r24">[24]</xref></p>
        <p>Patients on salicylates can develop toxicity if they begin acetazolamide. In addition, patients on sodium bicarbonate therapy have an increased risk of nephrolithiasis if using acetazolamide simultaneously.</p>
        <p>Patients using anti-folates, including methotrexate and trimethoprim, should not use acetazolamide.&#x000a0;Also, patients on any other carbonic anhydrase inhibitor should avoid this medication. Patients with a previous history of developing a serious rash should avoid the usage of acetazolamide as it can induce Stevens-Johnson syndrome.<xref ref-type="bibr" rid="article-17077.r25">[25]</xref></p>
      </sec>
      <sec id="article-17077.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>CBC and platelet counts are obtained on patients&#x000a0;at initiation of acetazolamide therapy and at regular intervals during therapy as acetazolamide is a sulfa drug. If&#x000a0;there is a significant change from the baseline,&#x000a0;discontinue the therapy. It is also recommended to monitor&#x000a0;serum electrolytes&#x000a0;periodically.<xref ref-type="bibr" rid="article-17077.r26">[26]</xref></p>
      </sec>
      <sec id="article-17077.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There have been reports of central nervous system (CNS) toxicity with coma.<xref ref-type="bibr" rid="article-17077.r27">[27]</xref>&#x000a0;In addition, hyperchloremic metabolic acidosis and electrolyte disturbances are usually seen in acetazolamide overdose. Therefore, clinicians should rapidly obtain serum electrolyte levels (especially serum potassium) and arterial blood gas analysis.&#x000a0;According to&#x000a0;product&#x000a0;labeling, there is no specific antidote to acetazolamide; hence treatment is usually supportive. Bicarbonate administration can usually correct metabolic acidosis. Despite its plasma protein binding and high RBC distribution, acetazolamide may be dialyzable. Dialysis may be especially valuable in managing acetazolamide overdosage complicated with acute kidney injury.</p>
      </sec>
      <sec id="article-17077.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Acetazolamide is not frequently used in clinical medicine, but clinicians need to know&#x000a0;the drug's adverse effects and contraindications. Patients require education from the team, including the clinician, nurse, and pharmacist, on the dose and indications of the drug and to report any side effects. Because there is no antidote to acetazolamide, it is essential to emphasize to the patient to seek immediate care if there is an overdose. The prescriber should work with the pharmacist on medication reconciliation to ensure no drug-drug interactions.&#x000a0;The prescriber should also use Tall Man (mixed case) lettering for the prescription of acetazolamide which is included in&#x000a0;look-alike-sound-alike drugs.<xref ref-type="bibr" rid="article-17077.r11">[11]</xref></p>
        <p>Pharmacists should also verify that the prescription&#x000a0;as acetazolamide is included in the ISMP (Institute for Safe Medication Practices) medication list to avoid confusion.<xref ref-type="bibr" rid="article-17077.r28">[28]</xref> The nurse should be able to monitor the patient on subsequent visits, counsel on medication administration, and verify patient adherence. Nursing is often a bridge between the prescriber, pharmacist, and other clinicians. All interprofessional team members must document their findings in the patient's record whenever they interact with them. They are also responsible for&#x000a0;communicating to the appropriate team members if any changes in the patient's status may merit attention. The interprofessional healthcare team can optimize therapy with acetazolamide while minimizing adverse events, resulting in better therapeutic outcomes for the patient. [Level 5]</p>
      </sec>
      <sec id="article-17077.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17077&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17077">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17077/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17077">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17077.s11">
        <title>References</title>
        <ref id="article-17077.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassamali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide: a forgotten diuretic agent.</article-title>
            <source>Cardiol Rev</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>276</fpage>
            <page-range>276-8</page-range>
            <pub-id pub-id-type="pmid">21983315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lusthaus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Current management of glaucoma.</article-title>
            <source>Med J Aust</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>210</volume>
            <issue>4</issue>
            <fpage>180</fpage>
            <page-range>180-187</page-range>
            <pub-id pub-id-type="pmid">30767238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wall</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on Idiopathic Intracranial Hypertension.</article-title>
            <source>Neurol Clin</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-57</page-range>
            <pub-id pub-id-type="pmid">27886895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wongboonsin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thongprayoon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bathini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide Therapy in Patients with Heart Failure: A Meta-Analysis.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>12</day>
            <volume>8</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30871038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toussaint</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kenefick</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Petrassi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Muza</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Charkoudian</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Altitude, Acute Mountain Sickness, and Acetazolamide: Recommendations for Rapid Ascent.</article-title>
            <source>High Alt Med Biol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-13</page-range>
            <pub-id pub-id-type="pmid">32975448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>KMA</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Sporadic adult-onset brainstem hyperkalemic periodic paralysis masquerading as recurrent transient ischemic attacks.</article-title>
            <source>Clin Case Rep</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>e05609</fpage>
            <pub-id pub-id-type="pmid">35317066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Berkel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elefritz</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Evaluating off-label uses of acetazolamide.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2018</year>
            <month>Apr</month>
            <day>15</day>
            <volume>75</volume>
            <issue>8</issue>
            <fpage>524</fpage>
            <page-range>524-531</page-range>
            <pub-id pub-id-type="pmid">29626002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmickl</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Verbraecken</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Javaheri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis.</article-title>
            <source>Chest</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>158</volume>
            <issue>6</issue>
            <fpage>2632</fpage>
            <page-range>2632-2645</page-range>
            <pub-id pub-id-type="pmid">32768459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Exome analysis of connective tissue dysplasia: death and rebirth of clinical genetics?</article-title>
            <source>Am J Med Genet A</source>
            <year>2014</year>
            <month>May</month>
            <volume>164A</volume>
            <issue>5</issue>
            <fpage>1209</fpage>
            <page-range>1209-12</page-range>
            <pub-id pub-id-type="pmid">24664531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ku</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bazargan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial.</article-title>
            <source>Intern Med J</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-362</page-range>
            <pub-id pub-id-type="pmid">31403755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leaf</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness.</article-title>
            <source>J Appl Physiol (1985)</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>1313</fpage>
            <page-range>1313-22</page-range>
            <pub-id pub-id-type="pmid">17023566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loiselle</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>de Kleine</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Dijk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jansonius</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Intraocular and intracranial pressure in glaucoma patients taking acetazolamide.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>e0234690</fpage>
            <pub-id pub-id-type="pmid">32555666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozsoy</surname>
                <given-names>HZ</given-names>
              </name>
            </person-group>
            <article-title>Anticonvulsant Effects of Carbonic Anhydrase Inhibitors: The Enigmatic Link Between Carbonic Anhydrases and Electrical Activity of the Brain.</article-title>
            <source>Neurochem Res</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>2783</fpage>
            <page-range>2783-2799</page-range>
            <pub-id pub-id-type="pmid">34226984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Low</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schedlbauer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grocott</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>Oct</month>
            <day>18</day>
            <volume>345</volume>
            <fpage>e6779</fpage>
            <pub-id pub-id-type="pmid">23081689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falardeau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lobb</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maxfield</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Tanne</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The use of acetazolamide during pregnancy in intracranial hypertension patients.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-12</page-range>
            <pub-id pub-id-type="pmid">22635167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Acetazolamide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katayama</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takanashi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies.</article-title>
            <source>Brain Dev</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>150</fpage>
            <page-range>150-4</page-range>
            <pub-id pub-id-type="pmid">11934510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogasawara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography in patients with major cerebral artery steno-occlusive diseases.</article-title>
            <source>Neurol Med Chir (Tokyo)</source>
            <year>2011</year>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>479</fpage>
            <page-range>479-83</page-range>
            <pub-id pub-id-type="pmid">21785240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaidi</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Kinnear</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycaemic agents: comparing enzymatic with diuresis induced metabolic acidosis following intraocular surgery in diabetes.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2004</year>
            <month>May</month>
            <volume>88</volume>
            <issue>5</issue>
            <fpage>714</fpage>
            <page-range>714-5</page-range>
            <pub-id pub-id-type="pmid">15090429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moviat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pickkers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Voort</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>van der Hoeven</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients.</article-title>
            <source>Crit Care</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>R14</fpage>
            <pub-id pub-id-type="pmid">16420662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Platt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies.</article-title>
            <source>Arch Neurol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>527</fpage>
            <page-range>527-9</page-range>
            <pub-id pub-id-type="pmid">22158718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macau</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Use of acetazolamide in lithium-induced nephrogenic diabetes insipidus: a case report.</article-title>
            <source>Endocrinol Diabetes Metab Case Rep</source>
            <year>2018</year>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29479446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vantzelfde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>17</day>
            <volume>375</volume>
            <issue>20</issue>
            <fpage>2008</fpage>
            <page-range>2008-2009</page-range>
            <pub-id pub-id-type="pmid">27959610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Her</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kil</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson syndrome induced by acetazolamide.</article-title>
            <source>J Dermatol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>272</fpage>
            <page-range>272-5</page-range>
            <pub-id pub-id-type="pmid">21342230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wile</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diuretics: a review.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>Pt 5</issue>
            <fpage>419</fpage>
            <page-range>419-31</page-range>
            <pub-id pub-id-type="pmid">22783025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerber</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>de Mello</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>KBA</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Wawrzeniak</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Rech</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide Intoxication in an Elderly Patient with Diabetes and Chronic Renal Failure after Cataract Surgery.</article-title>
            <source>Case Rep Crit Care</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>3764972</fpage>
            <pub-id pub-id-type="pmid">32082641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17077.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <article-title>ISMP Medication Error Report Analysis.</article-title>
            <source>Hosp Pharm</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>455</fpage>
            <page-range>455-7</page-range>
            <pub-id pub-id-type="pmid">24421503</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
